Emerging Sialylated Class R Lipooligosaccharides in Campylobacter jejuni from Seagulls Has the Potential to Trigger Guillain-Barré Syndrome - Yunnan Province, China, 2018-2023

Xiaoli Chen; Yixin Gu; Hairui Wang; Guilan Zhou; Xin Zhang; Chang Liu; Zhujun Shao; Jianzhong Zhang; Maojun Zhang

doi:10.46234/ccdcw2024.237

Emerging Sialylated Class R Lipooligosaccharides in Campylobacter jejuni from Seagulls Has the Potential to Trigger Guillain-Barré Syndrome - Yunnan Province, China, 2018-2023

China CDC Wkly. 2024 Nov 8;6(45):1177-1182. doi: 10.46234/ccdcw2024.237.

Authors

Xiaoli Chen¹, Yixin Gu¹, Hairui Wang¹, Guilan Zhou¹, Xin Zhang¹, Chang Liu¹, Zhujun Shao¹, Jianzhong Zhang¹, Maojun Zhang¹

Affiliation

¹ National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

Abstract

What is already known about this topic?: Lipooligosaccharides from Campylobacter jejuni (C. jejuni) have a mimicry antigen structure with gangliosides, which explains the mechanism by which C. jejuni caused Guillain-Barré syndrome (GBS).

What is added by this report?: All 12 C. jejuni strains with class R LOSs and specific serotypes were isolated from seagulls in south China. These emerging C. jejuni strains had ganglioside-mimicry antigen structures and possessed a high potential for triggering GBS.

What are the implications for public health practice?: Sialylated lipooligosaccharides (LOS) class R with GBS-associated serotypes isolated from seagulls highlight the risk of induced GBS around coastal or lakeside areas.

Keywords: Campylobacter jejuni; Genetic and antigenicity analysis; Guillain-Barre syndrome; emerging class R LOS.

Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2024.

Grants and funding

Supported by National Key Research and Development Program of China (2021YFC2301000), Research on detection and tracing of important pathogen combinations, identification and prevention of drug resistance hazards (SZSM201803081), and Project for Gonorrhea vaccine development (2023110024000074)